Medarex & Bristol-Myers Show Positive Metastatic Melanoma Data (BMY, MEDX)

By Douglas A. McIntyre Published Sep 15, 9:26AM EDT

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

There is some very hopeful data out there this morning on cancer survival. Bristol-Myers Squibb Co. (NYSE: BMY) and Medarex, Inc. (NASDAQ: MEDX) have released updated survival data from three Phase II studies of ipilimumab in patients with advanced metastatic melanoma in Stage III or IV levels who had previously been treated showing that approximately half of patients who received ipilimumab remained alive beyond one year.

The results are based on follow-up of the patient population fromstudies 008, 022 and 007 and show a consistent one-year survival ratebetween 47% and 51% as follows:

One-year survival rate of 47% in patients who had progressed while onor after receiving standard treatment (Study 008);follow-up for survival was up to 24.8 months.
One-year survival rate of 48% in patients who were previously treated,relapsed or failed to respond to experimental treatment or were unableto tolerate currently approved therapies (Study 022);follow-up for survival was up to 21.88 months.
One-year survival rate of 51% in patients previously treated withtherapy other than ipilimumab (Study 007); follow-upfor survival was up to 26.32 months.

Currently shares are up over 2% at $7.05. If the markets weren’t doingso poorly today on the bailout mergers and failures in the financialstocks then this might be getting more attention.

Jon C. Ogg
September 15, 2008

About the Author Douglas A. McIntyre →

Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.

McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.

His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.

A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.

TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.

McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.